AdvaMed President & CEO Provides COVID-19 Update on Bloomberg Radio

The 18th annual Pulse of the MedTech Industry report finds the medical technology industry continuing to push at new frontiers, as ongoing breakthroughs in MedTech AI and renewed hope for MedTech M&A hold out the possibility of making devices smarter, smaller and more personalized.

The investments being made in our domestic semiconductor chip manufacturing base under the CHIPS and Science Act are critical for the medtech industry and the millions of patients who rely on the life-saving devices the medtech industry develops.

In a new op-ed in RealClear Health, AdvaMed President and CEO Scott Whitaker called on the Biden Administration to ensure the medtech industry is considered as it implements policies to strengthen domestic supply chains.

Today, AdvaMed, the Medtech Association, released the following statement from President and CEO Scott Whitaker on the recent actions to strengthen supply chains announced by President Biden as part of the inaugural convening of the White House Council on Supply Chain Resilience:

 The United States International Trade Commission (USITC) released its highly anticipated report,“COVID-19 Diagnostics and Therapeutics, Supply, Demand, and TRIPS Agreement Flexibilities” on October 17. Evidence presented in the 496-page report supports AdvaMed’s position that there is no justification for the World Trade Organization (WTO) to waive intellectual property protection for products used to treat or diagnose COVID-19.

Today, AdvaMed marked the one year anniversary of the signing of the bipartisan CHIPS and Science Act and called on the Biden Administration to ensure, as implementation moves forward, that the medtech industry – including their need for mature and current chips – continues to be a priority.

AdvaMed, the Medtech Association, today released a white paper recommending six priority areas including public-private partnerships, facilitating transportation, and supportive policies for building medical technology supply chain resilience.

Cary Vance, President and CEO of Titan Medical, joined AdvaMed’s Scott Whitaker on the Medtech POV podcast to share his experience leading a small medical device company through the regulatory process as they transition from design to manufacturing.